Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

ClinicalTrials.gov ID: NCT03973333

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03973333. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as Single Agent and in Combination With Atezolizumab in HLA-A*0201-positive Patients With Advanced MAGE-A4-positive Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

IMC-C103C is an immune mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen MAGE-A4. This is a first-in-human trial designed to evaluate the safety and efficacy of IMC-C103C in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for MAGE-A4.

Study identification

NCT ID: NCT03973333
Recruitment status: Withdrawn
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Immunocore Ltd; Industry
Enrollment: Not listed

Conditions and interventions

Conditions

Select Advanced Solid Tumors

Interventions

IMC-C103C Drug
Atezolizumab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 17, 2019 (Estimated)
Primary completion: Sep 25, 2023 (Estimated)
Completion: Sep 25, 2023 (Estimated)
Last update posted: Oct 18, 2024

2019 – 2023

United States locations

U.S. sites: 10
U.S. states: 8
U.S. cities: 10

Facility	City	State	ZIP	Site status
The Angeles Clinic and Research Institute	Los Angeles	California	90025	—
University of California Davis Comprehenvise Cancer Center	Sacramento	California	95817	—
University of Colorado Cancer Center	Aurora	Colorado	80045	—
The University of Chicago Medicine & Biological Sciences	Chicago	Illinois	60637	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
Oklahoma University Medical Center	Oklahoma City	Oklahoma	73104	—
Thomas Jefferson University Hospital	Philadelphia	Pennsylvania	19107	—
UPMC Cancer Center	Pittsburgh	Pennsylvania	15213	—
Sarah Cannon Research Institute at Tennessee Oncology	Nashville	Tennessee	37203	—
MD Anderson Cancer Center	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03973333, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 18, 2024 · Synced Nov 14, 2026